Octreotide Does Not Prevent Pancreatic Fistula Following Pancreatoduodenectomy in Patients with Soft Pancreas and Non-dilated Duct: A Prospective Randomized Controlled Trial.

Kurumboor P, Palaniswami KN, Pramil K, George D, Ponnambathayil S, Varma D, Aikot S

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract25 Aug 2015Cited by 50 (Europe PMC)

PMID26302879DOI10.1007/s11605-015-2925-xPepBankPUB-26302879

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with soft pancreas and non-dilated duct after pancreatoduodenectomy, clinically significant pancreatic fistula (grades B and C) occurred in 10.9% with octreotide versus 18.5% without octreotide (p = ns).
In plain wordsAfter pancreas surgery in patients with a soft pancreas and normal-sized duct, clinically significant fistulas were less frequent with octreotide than without, but not significantly.
Peptide
Octreotide
Outcome
DecreaseClinically significant pancreatic fistula
Study
n = 109
Comparator
No octreotide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Measurements
Fistula rate
10.9%
octreotide
Fistula rate
18.5%
control
Source sentences
Summary
The rates of clinically significant pancreatic fistulae (grades B and C) were 10.9 and 18.5 % (p = ns), and morbidity was 18 and 29.6 % (p = ns), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients undergoing elective pancreatoduodenectomy with soft pancreas and non-dilated duct were randomized to octreotide group versus no octreotide-the control group.
Summary · context
There were 55 patients in octreotide group and 54 in the control group.
Report a problemFND-2630287901
02HumanRandomized controlled trialSafety outcome
In patients with soft pancreas and non-dilated duct after pancreatoduodenectomy, morbidity was 18% with octreotide versus 29.6% without octreotide (p = ns).
In plain wordsAfter pancreas surgery in patients with a soft pancreas and normal-sized duct, morbidity was lower with octreotide than without, but not significantly.
Peptide
Octreotide
Outcome
DecreaseMorbidity
Study
n = 109
Comparator
No octreotide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Morbidity rate
18%
octreotide
Morbidity rate
29.6%
control
Source sentences
Summary
The rates of clinically significant pancreatic fistulae (grades B and C) were 10.9 and 18.5 % (p = ns), and morbidity was 18 and 29.6 % (p = ns), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients undergoing elective pancreatoduodenectomy with soft pancreas and non-dilated duct were randomized to octreotide group versus no octreotide-the control group.
Summary · context
There were 55 patients in octreotide group and 54 in the control group.
Report a problemFND-2630287902
03HumanRandomized controlled trialEfficacy outcome
In patients with soft pancreas and non-dilated duct after pancreatoduodenectomy, those receiving octreotide resumed oral diet earlier than controls.
In plain wordsAfter pancreas surgery in patients with a soft pancreas and normal-sized duct, those receiving octreotide resumed eating earlier than controls.
Peptide
Octreotide
Outcome
DecreaseResumption of oral diet
Study
n = 109
Comparator
No octreotide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Patients who received octreotide resumed oral diet early and had a shorter hospital stay.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients undergoing elective pancreatoduodenectomy with soft pancreas and non-dilated duct were randomized to octreotide group versus no octreotide-the control group.
Summary · context
There were 55 patients in octreotide group and 54 in the control group.
Report a problemFND-2630287903
04HumanRandomized controlled trialEfficacy outcome
In patients with soft pancreas and non-dilated duct after pancreatoduodenectomy, octreotide recipients had a shorter hospital stay than controls, which the conclusion describes as a trend.
In plain wordsAfter pancreas surgery in patients with a soft pancreas and normal-sized duct, octreotide recipients had a shorter hospital stay than controls, described as a trend.
Peptide
Octreotide
Outcome
DecreaseHospital stay
Study
n = 109
Comparator
No octreotide
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Patients who received octreotide resumed oral diet early and had a shorter hospital stay.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients undergoing elective pancreatoduodenectomy with soft pancreas and non-dilated duct were randomized to octreotide group versus no octreotide-the control group.
Summary · context
There were 55 patients in octreotide group and 54 in the control group.
Summary · context
This study demonstrated no statistical difference in pancreatic fistulae with the use of octreotide, though there was a trend towards fewer incidences of pancreatic fistulae, morbidity and shorter hospital stay.
Report a problemFND-2630287904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01301222

Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas

PVS Memorial Hospitaln = 110Sept 2010 to Feb 2015

Pancreatic Fistula

Trial page ClinicalTrials.govUpdated 24 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.